The trading price of Lyell Immunopharma Inc (NASDAQ:LYEL) closed higher on Thursday, March 29, closing at $2.23, 9.31% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $3.97 and a 52-week low of $1.32. Over the past month, the stock has lost -21.48% in value.
Lyell Immunopharma Inc, whose market valuation is $566.64 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.21 per share this quarter, however they have predicted annual earnings per share of -$0.85 for 2024 and -$0.89 for 2025. It means analysts are expecting annual earnings per share growth of 8.60% this year and -4.70% next year.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Lyell Immunopharma Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest LYEL has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
A quick review shows that LYEL’s price is currently -2.98% off the SMA20 and 3.82% off the SMA50. The RSI metric on the 14-day chart is currently showing 51.91, and weekly volatility stands at 6.46%. When measured over the past 30 days, the indicator reaches 9.75%. Lyell Immunopharma Inc (NASDAQ:LYEL)’s beta value is currently sitting at -0.58, while the Average True Range indicator is currently displaying 0.19.
To see how Lyell Immunopharma Inc stock has been performing in comparison to its peers in the industry, here are the numbers: LYEL stock’s performance was 9.31% in the latest trading, and 0.45% in the past year.
An evaluation of the daily trading volume of Lyell Immunopharma Inc (NASDAQ:LYEL) indicates that the 3-month average is 1.02 million. However, this figure has increased over the past 10 days to an average of 0.86 million.
Currently, records show that 253.96 million of the company’s shares remain outstanding. The insiders hold 54.14% of outstanding shares, whereas institutions hold 27.92%. The stats also highlight that short interest as of Mar 15, 2024, stood at 10.38 million shares, resulting in a short ratio of 10.88 at that time. From this, we can conclude that short interest is 4.08% of the company’s total outstanding shares. It is noteworthy that short shares in March were down slightly from the previous month’s figure, which was 18.13 million. However, since the stock’s price has seen 14.95% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
